Urinary AD7c-NTP Evaluates Cognition Impairment and Differentially Diagnoses AD and MCI.

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY American Journal of Alzheimers Disease and Other Dementias Pub Date : 2022-01-01 DOI:10.1177/15333175221115247

Ming-Ran Xu, Rong-Fang Dai, Qing-Qi Wei, Jun Wang, Yue-Ying Feng, Ying Hu

{"title":"Urinary AD7c-NTP Evaluates Cognition Impairment and Differentially Diagnoses AD and MCI.","authors":"Ming-Ran Xu, Rong-Fang Dai, Qing-Qi Wei, Jun Wang, Yue-Ying Feng, Ying Hu","doi":"10.1177/15333175221115247","DOIUrl":null,"url":null,"abstract":"The AD7c-NTP is a promising biomarker for AD diagnosis. However, the exact urinary AD7c-NTP concentration to differentiate AD from the mild cognitive impairment (MCI) remains inconclusive. We enrolled 98 and 90 clinical defined AD and MCI patients, respectively, and access their cognition impairment with Neuropsychiatric Inventory (NPI) and Mental State Examination (MMSE) along with their urinary AD7c-NTP. We demonstrated that urinary AD7c-NTP level in sequence from high to low was AD, MCI, and healthy groups (P < .01), and the AD7c-NTP was positively and negatively correlated with the NPI and MMSE scores, respectively. Additionally, AD7c-NTP well-matched NPI subscale scores, including agitation, depression, and apathy (P < .05). Importantly, the optimal cut-off AD7c-NTP level to distinguish the AD and MCI was .94 ng/mL (sensitivity 85.71% & specificity 73.91%). Conclusively, urinary AD7c-NTP could be used for cognition impairment evaluation and differentiated diagnosis of AD and MCI.","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581138/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15333175221115247","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The AD7c-NTP is a promising biomarker for AD diagnosis. However, the exact urinary AD7c-NTP concentration to differentiate AD from the mild cognitive impairment (MCI) remains inconclusive. We enrolled 98 and 90 clinical defined AD and MCI patients, respectively, and access their cognition impairment with Neuropsychiatric Inventory (NPI) and Mental State Examination (MMSE) along with their urinary AD7c-NTP. We demonstrated that urinary AD7c-NTP level in sequence from high to low was AD, MCI, and healthy groups (P < .01), and the AD7c-NTP was positively and negatively correlated with the NPI and MMSE scores, respectively. Additionally, AD7c-NTP well-matched NPI subscale scores, including agitation, depression, and apathy (P < .05). Importantly, the optimal cut-off AD7c-NTP level to distinguish the AD and MCI was .94 ng/mL (sensitivity 85.71% & specificity 73.91%). Conclusively, urinary AD7c-NTP could be used for cognition impairment evaluation and differentiated diagnosis of AD and MCI.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

尿液 AD7c-NTP 可评估认知障碍，并对注意力缺失症和 MCI 进行鉴别诊断。

AD7c-NTP是一种很有希望用于诊断AD的生物标志物。然而，尿液中AD7c-NTP的确切浓度如何区分AD和轻度认知障碍（MCI）仍无定论。我们分别招募了 98 名和 90 名临床定义的 AD 和 MCI 患者，通过神经精神量表（NPI）和精神状态检查（MMSE）以及尿液中的 AD7c-NTP 检测他们的认知障碍。结果表明，AD、MCI 和健康组的尿 AD7c-NTP 水平由高到低依次递增（P < .01），AD7c-NTP 与 NPI 和 MMSE 分数分别呈正相关和负相关。此外，AD7c-NTP 与包括躁动、抑郁和冷漠在内的 NPI 分量表得分非常匹配（P < .05）。重要的是，区分 AD 和 MCI 的最佳 AD7c-NTP 临界值为 0.94 ng/mL（灵敏度为 85.71%，特异度为 73.91%）。最后，尿液中的AD7c-NTP可用于认知障碍评估和AD与MCI的鉴别诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American Journal of Alzheimers Disease and Other Dementias GERIATRICS & GERONTOLOGY-CLINICAL NEUROLOGY

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).